China Biologic Products Inc (CBPO) : Baring Asset Management Ltd scooped up 110,599 additional shares in China Biologic Products Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 25, 2016. The investment management firm now holds a total of 128,784 shares of China Biologic Products Inc which is valued at $15,067,728.China Biologic Products Inc makes up approximately 1.24% of Baring Asset Management Ltd’s portfolio.
China Biologic Products Inc opened for trading at $117.44 and hit $120.945 on the upside on Monday, eventually ending the session at $120.43, with a gain of 2.93% or 3.43 points. The heightened volatility saw the trading volume jump to 2,96,878 shares. Company has a market cap of $3,202 M.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa reduced its stake in CBPO by selling 37 shares or 0.26% in the most recent quarter. The Hedge Fund company now holds 14,214 shares of CBPO which is valued at $1,829,910. China Biologic Products Inc makes up approx 0.01% of Bnp Paribas Arbitrage Sa’s portfolio. Quotient Investors added CBPO to its portfolio by purchasing 11,240 company shares during the most recent quarter which is valued at $1,386,904. China Biologic Products Inc makes up approx 0.50% of Quotient Investors’s portfolio.Simplex Trading boosted its stake in CBPO in the latest quarter, The investment management firm added 3,626 additional shares and now holds a total of 6,071 shares of China Biologic Products Inc which is valued at $749,101. China Biologic Products Inc makes up approx 0.12% of Simplex Trading’s portfolio.
On the company’s financial health, China Biologic Products Inc reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.20 according to the earnings call on Feb 25, 2016. Analyst had a consensus of $0.54. The company had revenue of $68.30 million for the quarter, compared to analysts expectations of $67.16 million. The company’s revenue was up 17.8% compared to the same quarter last year.
Many Wall Street Analysts have commented on China Biologic Products Inc. China Biologic Products Inc was Downgraded by Credit Suisse to ” Neutral” on Mar 1, 2016.
China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).